CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...5152535455565758596061...39323933»
  • ||||||||||  IVX037 / ImmVirx
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (clinicaltrials.gov) -  Aug 26, 2024   
    P1,  N=70, Recruiting, 
    N=40 --> 70 | Trial completion date: Sep 2024 --> Nov 2026 | Trial primary completion date: Sep 2024 --> Sep 2026
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date:  Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma (clinicaltrials.gov) -  Aug 26, 2024   
    P2,  N=26, Recruiting, 
    N=40 --> 70 | Trial completion date: Sep 2024 --> Nov 2026 | Trial primary completion date: Sep 2024 --> Sep 2026 Trial completion date: Feb 2025 --> May 2026
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    P2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases:  Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. (Pubmed Central) -  Aug 24, 2024   
    The post-hoc evaluation of dynamic circulating tumor DNA using next generation sequencing and the analysis of peripheral immune proteomics landscape using Olink revealed that lower variant allele frequency (VAF) at baseline, greater reduction in VAF on treatment, and a hot peripheral macroenvironment were associated with the treatment response independently. Our study showed the antitumor activity of tislelizumab, cetuximab, and irinotecan combination with a tolerable safety profile in previously treated MSS and RAS WT mCRC.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Review, Journal:  Autologous stem cell transplantation in AL amyloidosis: Muddy waters. (Pubmed Central) -  Aug 24, 2024   
    With the advent of bortezomib and daratumumab based induction therapy, nearly all patients can achieve deep hematological responses but follow up for daratumumab based induction is short...Major organ dysfunction PFS (MOD-PFS) adds to PFS and is a composite endpoint of PFS, renal and cardiac organ progression, and overall survival. It is currently unknown which consolidative approach (ASCT or non-ASCT) will generate improved outcomes across the MOD-PFS spectrum a question the recently opened S2213 trial will attempt to answer.
  • ||||||||||  Kimmtrak (tebentafusp-tebn) / Immunocore
    Journal:  Exudative subretinal fluid associated with tebentafusp immunotherapy. (Pubmed Central) -  Aug 24, 2024   
    The compounds have demonstrated notable binding affinity in virtual screening and multi-stage molecular docking analysis, surpassing the controls, Erlotinib and Bevacizumab No abstract available
  • ||||||||||  P1 data, Journal, Checkpoint inhibition:  Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. (Pubmed Central) -  Aug 24, 2024   
    This analysis features the largest prospectively evaluated cohort of patients treated with combination ablative SBRT and ICI to date and provides context for future trial design. We conclude that multi-site SBRT and ICI can be safely co-administered when SBRT is delivered with prioritization of normal tissue constraints.
  • ||||||||||  Tecvayli (teclistamab-cqyv) / Genmab, J&J
    Journal:  Teclistamab-Associated Sclerouveitis with Hypopyon. (Pubmed Central) -  Aug 23, 2024   
    The findings indicate that evaluating the financial implications of high-cost treatments requires considering not only drug prices but also analysis of total cost increase. Teclistamab, a novel bispecific antibody recently approved for the treatment of relapsed or refractory multiple myeloma, may be associated with sclerouveitis with hypopyon.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, PD(L)-1 Biomarker, IO biomarker:  Multiplying Brown Spots. (Pubmed Central) -  Aug 23, 2024   
    Furthermore, we show documented serial improvement in the patient's ocular and systemic disease with treatment. This case as one of the longest surviving confirmed cases of a patient with bilateral diffuse uveal melanocytic proliferation.
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie
    Journal:  Clinical and Ultrasonographic Remission in Bio-na (Pubmed Central) -  Aug 23, 2024   
    UPARAREMUS is the first study evaluating the efficacy of upadacitinib in reaching both clinical and US remission in patients with RA. At 24
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Adverse events:  Secondary Adrenal Insufficiency as an Immune-Related Adverse Event of Pembrolizumab Therapy. (Pubmed Central) -  Aug 23, 2024   
    We present a case of secondary adrenal insufficiency while on pembrolizumab, in which the diagnosis was delayed due to a nonspecific clinical picture. This case highlights the importance of maintaining a high index of suspicion for endocrine dysfunction in patients treated with immune checkpoint inhibitors, as early recognition and appropriate intervention are paramount to preventing serious complications in these patients.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
    Journal, PD(L)-1 Biomarker, IO biomarker, Gene therapy:  IL-12 and PD-1 peptide combination gene therapy for the treatment of melanoma. (Pubmed Central) -  Aug 23, 2024   
    Finally, we tested the combination of pIL-12 GET therapy and peptide plasmids. We determined that pIL-12 GET therapeutic efficacy could be enhanced by combination with the plasmid encoding the pembrolizumab mouse homolog.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Journal, IO biomarker:  FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population. (Pubmed Central) -  Aug 23, 2024   
    However, we did not observe difference in response following treatment combining chemotherapy associated or not with daratumumab, an IgG1 mAb direct against CD38. Our findings suggest that FCGR3A F158V polymorphism can regulate the immune environment and affect the development of tumor plasma cells.
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
    P3 data, Journal:  Optimal patient profile for ofatumumab treatment: analysis of Russian data from the Phase 3 study (Pubmed Central) -  Aug 23, 2024   
    In a total group of 1.882 patients, a more positive effect of ofatumumab compared with teriflunomide was noted on the average annual incidence of exacerbations in men, younger people and with a mild baseline disability level - with a baseline EDSS level less than or equal to 3...This feature was also confirmed by analyzing the secondary endpoints of the study: the number of active foci on MRI and the confirmed progression of disability according to the EDSS scale. Analysis in clinical subgroups makes it possible to clarify the profile of patients in whom the greatest clinical effect can be expected when using this new drug for the treatment of MS.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal, Checkpoint inhibition:  Cardiogenic shock secondary to immune checkpoint inhibitor associated myocarditis. (Pubmed Central) -  Aug 23, 2024   
    Within days, his troponin and C-reactive protein levels decreased, and his left ventricular function improved. He was established on heart failure therapies and discharged from hospital 12?days later.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Blinatumomab infusion interruptions in pediatric patients rarely lead to readmission. (Pubmed Central) -  Aug 23, 2024   
    Clinical staff intervention was required in 31 (45%) cycles, only six (8.7%) cycles needed readmission. Management of outpatient blinatumomab infusions requires education and training of clinical staff and caregivers to quickly troubleshoot interruptions.
  • ||||||||||  Imdelltra (tarlatamab-dlle) / Amgen
    Review, Journal:  Tarlatamab: First Approval. (Pubmed Central) -  Aug 23, 2024   
    Tarlatamab is under regulatory review in Brazil, Canada, Israel and the UK, and clinical studies are underway in multiple countries. This article summarizes the milestones in the development of tarlatamab leading to this first approval for ES-SCLC with disease progression on or after platinum-based chemotherapy.